SCHEMBL4287200

SCHEMBL4287200

COC(=O)c1ccc2c(c1)N(C(C)=O)C(c1ccc(Cl)cc1Cl)C1=C(CC(C)(C)CC1=O)N2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
ALDH1A1 P00352 4/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
HSD17B10 Q99714 2/20 0.47
MAPT P10636 2/20 0.40
GLA P06280 1/20 0.40
CASP1 P29466 1/20 0.40
HTT P42858 1/20 0.40
KLK7 P49862 1/20 0.40
CASP7 P55210 1/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA7 P43166 2/20 0.40
KDM4E B2RXH2 1/20 0.39
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
CA4 P22748 1/20 0.37
BRD4 O60885 1/20 0.37
BRD2 P25440 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4287151 0.93 MEN1 (0.50) MEN1KMT2AALDH1A1SMN1; SMN2HSD17B10
SCHEMBL4289896 0.91 MEN1 (0.48) MEN1KMT2AALDH1A1SMN1; SMN2HSD17B10
SCHEMBL4291113 0.86 MEN1 (0.49) MEN1KMT2AALDH1A1SMN1; SMN2HSD17B10
SCHEMBL4300461 0.85 KMT2A (0.56) MEN1KMT2AALDH1A1SMN1; SMN2HSD17B10
SCHEMBL14583092 0.85 MEN1 (0.49) MEN1KMT2AALDH1A1SMN1; SMN2HSD17B10
SCHEMBL4287691 0.85 MEN1 (0.62) MEN1KMT2AALDH1A1SMN1; SMN2HSD17B10
SCHEMBL13704122 0.85 MEN1 (0.47) MEN1KMT2AALDH1A1SMN1; SMN2HSD17B10
SCHEMBL4290980 0.84 MEN1 (0.48) MEN1KMT2AALDH1A1SMN1; SMN2HSD17B10
SCHEMBL13704149 0.84 MEN1 (0.47) MEN1KMT2AALDH1A1SMN1; SMN2HSD17B10
SCHEMBL4287067 0.84 MEN1 (0.48) MEN1KMT2AALDH1A1SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221559-A1 BENZODIAZEPINES AS HCV INHIBITORS BONFANTI JEAN-FRANCOIS 2009-09-03 US disclosed
US-20090221559-A1 BENZODIAZEPINES AS HCV INHIBITORS BONFANTI JEAN-FRANCOIS 2009-09-03 US disclosed
US-20090221559-A1 BENZODIAZEPINES AS HCV INHIBITORS BONFANTI JEAN-FRANCOIS 2009-09-03 US disclosed
WO-2007026024-A2 BENZODIAZEPINES AS HCV INHIBITORS TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221559-A1 BENZODIAZEPINES AS HCV INHIBITORS GABRA5, GABRA4, GABRA3 MEN1 4829/4885KMT2A 1440/4885ALDH1A1 372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.